George L. Bakris, MD, a professor of medicine and the director of the American Heart Association-accredited Comprehensive Hypertension Center, University of Chicago Medicine, spoke about a new subgroup analysis of the FIGARO-DKD trial.

Researchers presented the secondary kidney outcomes of FIGARO-DKD, a randomized, double-blind, placebo-controlled phase 3 trial, at ASN Kidney Week. They found finerenone induced a pronounced reduction in albuminuria for patients with stage 1-4 chronic kidney disease and type 2 diabetes.

“Bottom line is that there was a 23% risk reduction in doubling of creatinine. Number two, and I think more important, there was a 20% reduction in time to dialysis. So, we reduced the time to dialysis by 20% in these people that did not necessarily have advanced kidney disease. They had eGFRs in the 60s with microalbuminuria,” he said.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

“
data-action=”subscribe”>
Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

American Society of Nephrology Annual Meeting